Cencora Inc.COR
▲ PositiveCapitalrelevance
Q2 results beat on adjusted EPS and full-year guidance raised.
Impact on stocks 1
Health Care
Cencora Inc.Cencora Q2 Earnings Call: Five Analyst Questions Highlight Growth Drivers
Earnings
Cencora reported second-quarter results that met revenue expectations and beat consensus on non-GAAP profitability, with management crediting specialty pharmaceuticals and digital transformation for the performance. Revenue was $84.75 billion versus analyst estimates of $84.43 billion, and adjusted EPS was $4.48 versus estimates of $4.35. The company slightly raised its full-year adjusted EPS guidance to $17.85 at the midpoint. During the earnings call, analysts from JPMorgan, Barclays, Evercore ISI, Deutsche Bank, and UBS questioned management on topics including U.S. pharma reacceleration, Part B versus Part D biosimilars, OneOncology growth sustainability, specialty logistics competition, and proposed ASP rule changes. CEO Robert Mauch and CFO Eva Boratto addressed these questions, emphasizing MSO strength, service intensity in infusion settings, integration progress, pharmaceutical-centric differentiation, and monitoring of policy developments.
Cencora Inc.Q2 results beat on adjusted EPS and full-year guidance raised.